Providence Health & Services
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Providence Health & Services sits in the top decile of US sponsors by registered trial count (#307 of 15,742 sponsors by registered trial count).
Providence Health & Services: 69 sponsored US clinical trials, 5 recruiting.
Providence Health & Services sponsors 69 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 32 completed. 6 of these trials are in Phase 3-4 (later-stage) and 47 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 4 trials.
Top-decile sponsor footprint
Providence Health & Services ranks in the top decile of sponsors by registered trial count (#307 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
32 of 45 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
69 total, page 2 of 2
Prevalence, Awareness and Management of Hypertension in Acute Care Personnel
NCT01655654
Multi-Drug Desensitization Protocol for Heart Transplant Candidates
NCT01556347
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
NCT01862900
Immunochemoradiotherapy in Patients With Pancreatic Cancer
NCT01342224
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
NCT01303705
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT01057212
The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer
NCT02575391
Effect and Utilization of Protected Time Among Interns on Extended Duty-Hour Call Shifts
NCT00983008
The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer
NCT02575313
Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC)
NCT00961376
A Trial of Single Port Laparoscopic Cholecystectomy Versus Four Port Laparoscopic Cholecystectomy
NCT00892879
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer
NCT00850785
Work Hour Reductions, Medical Errors, and Intern Well-Being at Providence St. Vincent Medical Center Intensive Care Unit
NCT00996320
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer
NCT00232206
Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer
NCT01644968
Carotid Artery Stenting With Protection Registry
NCT00318851
Angiotensin II Antagonism of TGF-Beta 1
NCT00320970
The Heart Institute of Spokane Diet Study
NCT00269425
Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation
NCT00302627
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 30 |
| Phase 2 | 17 |
| Phase 3 | 5 |
| Phase 4 | 1 |
What is open in the Providence Health & Services pipeline
5 recruiting of 69 indexed (7% open); 32 completed (46%).
Phase mix: 6 late (III/IV) vs 47 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Providence Health & Services: open-pipeline peers nationwide
Peers matched on 69 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Providence Health & Services sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 69 trials (± recruiting share)
- Mallinckrodt · 69 trials · 0% recruiting
- Texas Tech University · 69 trials · 17% recruiting
- University of Colorado, Boulder · 69 trials · 22% recruiting
- Procter and Gamble · 70 trials · 0% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Radicle Science · 7% recruiting · 55 trials
- Carol Fabian, MD · 7% recruiting · 14 trials
- Celldex Therapeutics · 7% recruiting · 42 trials
- Kaiser Permanente · 7% recruiting · 294 trials
Related
What to do with this Providence Health & Services page
69 registered trials is a research-attention snapshot, not an endorsement of Providence Health & Services or any single study.
- 5 of Providence Health & Services's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Providence Health & Services studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Providence Health & Services pipeline card: 69 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.